Biomarkers and methods of prediction
AssigneeHoffmann-La Roche Inc.
InventorsThomas Dieterle, Eric J. Niesor, Rosemarie Kientsch-Engel, Horst Klima, Fabian Model, Gabriela Bucklar, Vinzent Rolny
Life of this patent
Estimating the term…
Abstract
Subject of the present invention are biomarkers and methods for the identification of risk for subsequent cardiovascular event (e.g. coronary heart disease death, non-fatal myocardial infarction, ischemic stroke, hospitalizations for unstable angina pectotis, cardiac arrest) in patients that have experienced an acute coronary syndrome, comprising the detecting the level of NT-proBNP, homocysteine and CRP.
Claims19
A method for identifying a subject suffering from stable CHD, particularly with a documented recent Acute Coronary Syndrome (ACS), more particularly a post Acute Coronary Syndrome (ACS), most particularly a recent ACS as having an increased risk of a cardiovascular event, particularly an other cardiovascular event, more particularly a secondary cardiovascular event, the method comprising:
- a) detecting the amount of N-terminal of the pro-hormone brain natriuretic peptide (NT-proBNP), homocysteine and C-reactive protein (CRP) in a sample of a subject;
- b) comparing the amount of NT-proBNP, homocysteine and CRP to a reference amount of NT-proBNP, homocysteine and CRP;
- and
- c) identifying the subject as having an increased risk of a cardiovascular event, particularly an other cardiovascular event, more particularly a secondary cardiovascular event, if the amount of NT-proBNP, homocysteine and CRP in the sample is greater than the reference amount of NT-proBNP, homocysteine and CRP.
A method for identifying a subject as having an increased risk of experiencing a cardiovascular event, particularly an other cardiovascular event, in particular a secondary cardiovascular event, following an acute coronary syndrome, more particularly following a recent acute coronary syndrome, the method comprising:
- a) detecting the amount of N-terminal of the pro-hormone brain natriuretic peptide (NT-proBNP), homocysteine and C-reactive protein (CRP) in a sample of a subject;
- b) comparing the amount of NT-proBNP, homocysteine and CRP to a reference amount of NT-proBNP, homocysteine and CRP;
- and
- c) identifying the subject as having an increased risk of a cardiovascular event, particularly an other cardiovascular event, more particularly a secondary cardiovascular event, if the amount of NT-proBNP, homocysteine and CRP in the sample is greater than the reference amount of NT-proBNP, homocysteine and CRP.
-32. (canceled)
(canceled)
Dependencies are inferred from the claim text.